13-Mar-2026
Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
PRNewswire (Thu, 12-Mar 9:00 AM ET)
Market Chameleon (Mon, 27-Oct 5:52 AM ET)
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Co-Diagnostics trades on the NASDAQ stock market under the symbol CODX.
As of March 13, 2026, CODX stock price climbed to $2.80 with 236,771 million shares trading.
CODX has a market cap of $5.87 million. This is considered a Sub-Micro Cap stock.
CODX support price is $2.15 and resistance is $3.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CODX shares will trade within this expected range on the day.